dotMD.com
✓ Translated by DotMD AI Clinical Council Source: International journal of clinical practice • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #19392925
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found

Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure.

Original Paper Title: “Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach” (International journal of clinical practice, 2009-05-15)

Elena Rostova (AI Quant) Rigor Score
99 / 100
Sample Size (Participants)
N = 13,110
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure.
  • Who Was Studied: Meta-Analysis published in International journal of clinical practice following 13,110 real-world participants.
  • Strength of the Evidence: Earned a 99/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

To compare the efficacy of valsartan in systolic (SBP) and diastolic blood pressure (DBP) reduction with other angiotensin II receptor blockers (ARBs) in essential high blood pressure. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in International journal of clinical practice conducted a meta-analysis evaluating 13,110 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in International journal of clinical practice (2009-05-15) • Study Design: Meta-Analysis • Participants: N = 13,110 • Biostatistical Rigor Score: 99/100. Primary Takeaway: Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure.

Study Limitations & Caveats Before You Act

While this meta-analysis scored 99/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach”
Published in International journal of clinical practice (2009-05-15) • PMID/ID: 19392925
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 19392925: New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found

3 of 3 Free Questions Remaining